Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.